-
AzurRx Hits Enrollment Goal in Trial of Therapy for CF Patients with EPI
AzurRx has achieved its enrollment goal for a Phase 2 trial testing MS1819-SD in cystic fibrosis patients with exocrine pancreatic insufficiency. Read more about the trial here.
What do you think of this news?
Sorry, there were no replies found.
Log in to reply.